In today’s Pharmaceutical Executive Daily, Public Citizen files suit over undisclosed drug pricing agreements involving Pfizer and Eli Lilly, HHS releases new guidance aimed at lowering prescription drug costs through direct-to-consumer programs, and AstraZeneca enters a multibillion-dollar collaboration with CSPC Pharmaceutical Group.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, Public Citizen files suit over undisclosed drug pricing agreements involving Pfizer and Eli Lilly, HHS releases new guidance aimed at lowering prescription drug costs through direct-to-consumer programs, and AstraZeneca enters a multibillion-dollar collaboration with CSPC Pharmaceutical Group.
Public Citizen has filed a lawsuit against the Trump administration, alleging it failed to disclose key details of drug pricing agreements involving Pfizer and Eli Lilly. The suit raises transparency concerns around how federal drug pricing negotiations are conducted and what information is shared with the public.
Meanwhile, the Department of Health and Human Services has issued new guidance focused on lowering prescription drug prices through direct-to-consumer programs. The update outlines how manufacturers can more directly engage patients while aligning pricing strategies with federal affordability goals.
Finally, AstraZeneca has entered a multibillion-dollar collaboration agreement with China-based CSPC Pharmaceutical Group. The deal strengthens AstraZeneca’s presence in China and expands its pipeline through shared development and commercialization of multiple therapies.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
